Mandate

Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million

December 01, 2021 Capital Markets and Public M&A

Vinge advises Cell Impact AB (publ) in connection with a fully guaranteed rights issue which will provide Cell Impact with gross issue proceeds of SEK 349 million

Cell Impact is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique scalable method for high-velocity forming, Cell Impact Forming™, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

Vinge’s team consisted of Johan Larsson, Dain Hård Nevonen, Anna Jonsson, Rikard Lindahl, Joel Magnusson and Lorin Arabi.

 

Related

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026

Vinge has advised EQT managed Scaleup Europe Fund on its investment in Tandem Health

Vinge has advised EQT managed Scaleup Europe Fund as lead investor in Tandem Health's USD 100 million Series B investment round, with participation from existing investors Kinnevik, Northzone, Amino Collective and Visionaries. Tandem Health is an AI healthcare company founded in 2023 and headquartered in Sweden. Tandem Health operates as an AI partner within the healthcare sector across Europe, providing AI medical assistant support to clinicians in connection with patient visits.
September 15, 2026